Stoke Therapeutics, Inc. Common Stock STOK
i
Market dataready · fetched 2026-11-12T01:15:42.367Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T21:00:00.492673534Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-12T01:15:41.942742+00:00
Stoke Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 35.13 | 156.1% | 29.0% | 19.85 | 388.5% | 37.3% |
| 25Δ | 32.67 | 122.3% | 20.1% | 22.56 | 298.6% | 27.6% |
| 30Δ | 30.27 | 88.7% | 11.5% | 23.46 | 274.3% | 24.6% |
| 35Δ | 29.47 | 85.5% | 9.8% | 24.35 | 250.1% | 21.7% |
| 40Δ | 28.88 | 86.1% | 9.0% | 25.25 | 225.8% | 18.7% |
| 45Δ | 28.28 | 86.7% | 8.2% | 26.14 | 201.5% | 15.7% |
| 50Δ | 27.69 | 87.3% | 7.4% | 27.04 | 177.3% | 12.8% |
| 55Δ | 27.09 | 87.9% | 6.6% | 27.94 | 153.0% | 9.8% |
| 60Δ | 26.50 | 88.5% | 5.8% | 28.83 | 128.7% | 6.9% |
| 65Δ | 25.91 | 89.1% | 5.0% | 29.73 | 104.4% | 3.9% |
| 70Δ | 25.31 | 89.7% | 4.3% | 30.83 | 100.5% | 2.7% |
| 75Δ | 24.72 | 90.3% | 3.5% | 32.01 | 105.4% | 2.2% |
| 80Δ | 24.12 | 90.9% | 2.7% | 33.20 | 110.4% | 1.7% |
20Δ
- Pseudo strike
- 35.13
- IV
- 156.1%
- B/E move
- 29.0%
- Pseudo strike
- 19.85
- IV
- 388.5%
- B/E move
- 37.3%
25Δ
- Pseudo strike
- 32.67
- IV
- 122.3%
- B/E move
- 20.1%
- Pseudo strike
- 22.56
- IV
- 298.6%
- B/E move
- 27.6%
30Δ
- Pseudo strike
- 30.27
- IV
- 88.7%
- B/E move
- 11.5%
- Pseudo strike
- 23.46
- IV
- 274.3%
- B/E move
- 24.6%
35Δ
- Pseudo strike
- 29.47
- IV
- 85.5%
- B/E move
- 9.8%
- Pseudo strike
- 24.35
- IV
- 250.1%
- B/E move
- 21.7%
40Δ
- Pseudo strike
- 28.88
- IV
- 86.1%
- B/E move
- 9.0%
- Pseudo strike
- 25.25
- IV
- 225.8%
- B/E move
- 18.7%
45Δ
- Pseudo strike
- 28.28
- IV
- 86.7%
- B/E move
- 8.2%
- Pseudo strike
- 26.14
- IV
- 201.5%
- B/E move
- 15.7%
50Δ
- Pseudo strike
- 27.69
- IV
- 87.3%
- B/E move
- 7.4%
- Pseudo strike
- 27.04
- IV
- 177.3%
- B/E move
- 12.8%
55Δ
- Pseudo strike
- 27.09
- IV
- 87.9%
- B/E move
- 6.6%
- Pseudo strike
- 27.94
- IV
- 153.0%
- B/E move
- 9.8%
60Δ
- Pseudo strike
- 26.50
- IV
- 88.5%
- B/E move
- 5.8%
- Pseudo strike
- 28.83
- IV
- 128.7%
- B/E move
- 6.9%
65Δ
- Pseudo strike
- 25.91
- IV
- 89.1%
- B/E move
- 5.0%
- Pseudo strike
- 29.73
- IV
- 104.4%
- B/E move
- 3.9%
70Δ
- Pseudo strike
- 25.31
- IV
- 89.7%
- B/E move
- 4.3%
- Pseudo strike
- 30.83
- IV
- 100.5%
- B/E move
- 2.7%
75Δ
- Pseudo strike
- 24.72
- IV
- 90.3%
- B/E move
- 3.5%
- Pseudo strike
- 32.01
- IV
- 105.4%
- B/E move
- 2.2%
80Δ
- Pseudo strike
- 24.12
- IV
- 90.9%
- B/E move
- 2.7%
- Pseudo strike
- 33.20
- IV
- 110.4%
- B/E move
- 1.7%
Options history
Table
| Date | IV (%) |
|---|---|
| 77.26% | |
| 73.36% | |
| 77.07% | |
| 75.71% | |
| 77.24% | |
| 74.85% | |
| 80.45% | |
| 82.01% | |
| 79.35% | |
| 75.45% |
Biotechnology
STRO
Sutro Biopharma, Inc. is a clinical stage drug discovery, development and manufacturing company. The company is headquartered in South San Francisco, California.
More →STTK
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapies for the treatment of cancer and autoimmune diseases in the United States. The company is…
More →SVRA
Savara Inc. is a lung disease orphan company. The company is headquartered in Austin, Texas.
More →SYRE
Spyre Therapeutics, Inc., a biotechnology company, focuses on advancing a pipeline of antibody therapeutics for the treatment of inflammatory bowel disease by combining antibody…
More →TARA
Description unavailable
More →TARS
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new therapeutic candidates for ophthalmic conditions.…
More →